Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab in cancer cachexia with elevated GDF-15
jRCT2031220581Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ponsegromab in cancer anorexia-cachexia syndrome (CACS) (4 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in body weight for ponsegromab compared with placebo. Started Jan 2023; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on jRCT2031220581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220581.